Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Sales | 7,440 | 2,411 | 22,942 | 23,189 | 7,544 |
| Cost of Goods | 71 | 56 | 12 | 178 | 12 |
| Gross Profit | 7,369 | 2,355 | 22,931 | 23,011 | 7,532 |
| Operating Expenses | 22,581 | 20,839 | 17,790 | 20,093 | 17,204 |
| Operating Income | -15,140 | -18,428 | 5,153 | 3,096 | -9,660 |
| Other Income | 21 | 13 | 12 | 20 | 24 |
| Pre-tax Income | -15,119 | -18,416 | 5,165 | 3,116 | -9,636 |
| Net Income Continuous | -15,119 | -18,416 | 5,165 | 3,116 | -9,636 |
| Net Income | $-15,119 | $-18,416 | $5,165 | $3,116 | $-9,636 |
| EPS Basic Total Ops | -0.14 | -0.17 | 0.05 | 0.03 | -0.10 |
| EPS Basic Continuous Ops | -0.14 | -0.18 | 0.05 | 0.03 | -0.10 |
| EPS Diluted Total Ops | -0.14 | -0.17 | 0.05 | 0.03 | -0.10 |
| EPS Diluted Continuous Ops | -0.14 | -0.18 | 0.05 | 0.03 | -0.10 |
| EBITDA(a) | $-14,903 | $-18,184 | $5,392 | $3,383 | $-9,333 |